[1]陈彦防,隋晓梅,郝美丽,等.LINC00313结合miR-4429在非小细胞肺癌的诊断和预后中的作用及价值[J].医学信息,2025,38(02):82-87.[doi:10.3969/j.issn.1006-1959.2025.02.014]
　CHEN Yanfang,SUI Xiaomei,HAO Meili,et al.Role and Value of LINC00313 Combined with miR-4429 in the Diagnosis and Prognosis of Non-small Cell Lung Cancer[J].Journal of Medical Information,2025,38(02):82-87.[doi:10.3969/j.issn.1006-1959.2025.02.014]
点击复制

LINC00313结合miR-4429在非小细胞肺癌的诊断和预后中的作用及价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年02期
页码:
82-87
栏目:
论著
出版日期:
2025-01-15

文章信息/Info

Title:
Role and Value of LINC00313 Combined with miR-4429 in the Diagnosis and Prognosis of Non-small Cell Lung Cancer
文章编号:
1006-1959（2025）02-0082-06
作者:
陈彦防; 隋晓梅; 郝美丽; 张启富
山东第二医科大学附属医院放疗科，山东 潍坊 261031
Author(s):
CHEN Yanfang;  SUI Xiaomei;  HAO Meili;  ZHANG Qifu
Department of Radiotherapy, Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Shandong, China
关键词:
非小细胞肺癌; LINC00313; miR-4429; 诊断; 预后
Keywords:
Non-small cell lung cancer;  LINC00313;  miR-4429;  Diagnosis;  Prognosis
分类号:
R73
DOI:
10.3969/j.issn.1006-1959.2025.02.014
文献标志码:
A
摘要:
目的 探讨 LINC00313/miR-4429 在非小细胞肺癌（NSCLC）诊断和预后中的潜在作用和临床价值。方法 选择2016年1月-2018年5月在我院接受肿瘤切除术的128例NSCLC患者设为试验组。采集NSCLC静脉血样及肿瘤组织，将邻近的正常组织（距肿瘤组织边缘3 cm）样本设为对照组。通过反转录定量 PCR 检测观察 LINC00313 和 miR-4429 在 NSCLC 患者血清、组织和细胞系中的表达水平，观察LINC00313/miR-4429与NSCLC患者的临床病理特征之间的关系，通过 ROC 曲线分析评估诊断价值，Kaplan-Meier 生存分析和 Cox 回归分析预后价值。结果 LINC00313在NSCLC血清、组织和细胞系中的表达增加，而miR-4429的表达减少，LINC00313的过量表达抑制了NSCLC细胞中miR-4429的表达。LINC00313的表达水平与肿瘤大小、分化、淋巴结转移和TNM分期相关（P＜0.05），而miR-4429的表达水平与分化、淋巴结转移和TNM分期相关。ROC曲线显示，LINC00313和miR-4429具有很高的诊断价值；Kaplan-Meier曲线结果表明，LINC00313的高表达和miR-4429的低表达提示预后不良。结论 LINC00313和miR-4429的异位表达在NSCLC的诊断和预后中具有良好的临床意义，LINC00313/miR-4429可能为NSCLC的治疗提供一种新的生物标志物。
Abstract:
Objective To investigate the potential role and clinical value of LINC00313/miR-4429 in the diagnosis and prognosis of non-small cell lung cancer (NSCLC). Methods A total of 128 patients with NSCLC who underwent tumor resection in our hospital from January 2016 to May 2018 were selected as the experimental group. The venous blood samples and tumor tissues of NSCLC were collected, and the adjacent normal tissues (3 cm from the edge of tumor tissues) were set as the control group. The expression levels of LINC00313 and miR-4429 in serum, tissues and cell lines of NSCLC patients were observed by reverse transcription quantitative PCR. The relationship between LINC00313/miR-4429 and clinicopathological features of NSCLC patients was observed. The diagnostic value was evaluated by ROC curve analysis, and the prognostic value was analyzed by Kaplan-Meier survival analysis and Cox regression analysis. Results The expression of LINC00313 was increased in serum, tissues and cell lines of NSCLC, while the expression of miR-4429 was decreased, the overexpression of LINC00313 inhibited the expression of miR-4429 in NSCLC cells. The expression level of LINC00313 was correlated with tumor size, differentiation, lymph node metastasis and TNM stage (P<0.05), while the expression level of miR-4429 was correlated with differentiation, lymph node metastasis and TNM stage. ROC curve showed that LINC00313 and miR-4429 had high diagnostic value. Kaplan-Meier curve results showed that high expression of LINC00313 and low expression of miR-4429 indicated poor prognosis. Conclusion The ectopic expression of LINC00313 and miR-4429 has good clinical significance in the diagnosis and prognosis of NSCLC. LINC00313/miR-4429 may provide a new biomarker for the treatment of NSCLC.

参考文献/References:

[1]de Sousa VML,Carvalho L.Heterogeneity in Lung Cancer[J].Pathobiology:Journal of Immunopathology, Molecular and Cellular Biology,2018,85(1-2),96-107.[2]Xia C,Dong X,Li H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants[J].Chinese Medical Journal,2022,135(5):584-590.[3]Shetty A,Venkatesh T,Kabbekodu SP,et al.LncRNA-miRNA-mRNA regulatory axes in endometrial cancer:a comprehensive overview[J].Arch Gynecol Obstet,2022,306(5):1431-1447. [4]Kong W,Zhang L,Chen Y,et al.Cancer cell-derived exosomal LINC00313 induces M2 macrophage differentiation in non-small cell lung cancer[J].Clin Transl Oncol,2022,24(12):2395-2408.[5]Wu WJ,Yin H,Hu JJ,et al.Long noncoding RNA LINC00313 modulates papillary thyroid cancer tumorigenesis viasponging miR-4429[J].Neoplasma,2018,65(6):933-942. [6]Hong P,Yejing H,Biying Y,et al.miR-4429 Inhibits Tumor Progression and Epithelial-Mesenchymal Transition Via Targeting CDK6 in Clear Cell Renal Cell Carcinoma[J].Cancer Biother Radiopharm,2019,34(5):334-341.[7]Huabo H,Wei W,Zhener S,et al.MiR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m6A-caused stabilization of SEC62[J].Biochemical and Biophysical Research Communications,2019,517(4):581-587. [8]Hongbo S,Guimei F,Chunxia D,et al.miR-4429 sensitized cervical cancer cells to irradiation by targeting RAD51[J].Journal of Cellular Physiology,2020,235(1):185-193.[9]Rolfo C,Ordó?觡ez-Reyes C,Cardona AF.Immunotherapy Resistance in Non-Small Cell Lung Cancer: A Rubik’s Cube to Assemble[J].J Immunother Precis Oncol,2021,4(4):185-188.[10]Allemani C,Matsuda T,Carlo DV,et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].The Lancet,2018,391(10125):1023-1075.[11]Wang Y,Lu Z,Wang N,et al.Long noncoding RNA DANCR promotes colorectal cancer proliferation and metastasis viamiR-577 sponging[J].Exp Mol Med,2018,50(5):1-17.[12]Jafarzadeh A,Noori M,Sarrafzadeh S,et al.MicroRNA-383: A tumor suppressor miRNA in human cancer[J].Front Cell Dev Biol,2022,13(10):955486. [13]Liu X,Chen R,Liu L.SP1-DLEU1-miR-4429 feedback loop promotes cell proliferative and anti-apoptotic abilities in human glioblastoma[J].Bioscience Reports,2019,39(12):BSR20190994.[14]Liang L,Zheng YW,Wang YL.miR-4429Regulates the Proliferation,Migration,Invasion,and Epithelial-Mesenchymal Transition of Cervical Cancer by Targeting FOXM1[J].Cancer Management and Research,2020,12:1009-1010.[15]Murugan D,Rangasamy L.A perspective to weaponize microRNAs against lung cancer[J].Noncoding RNA Res,2022,8(1):18-32. [16]Yu W,Sun Z,Yang L,et al.lncRNA PTAR promotes NSCLC cell proliferation,migration and invasion by sponging microRNA-101[J].Molecular Medicine Reports,2019,20(5):4168-4174.[17]Peng W,He D,Shan B,et al.LINC81507 act as a competing endogenous RNA of miR-199b-5p to facilitate NSCLC proliferation and metastasis via regulating the CAV1/STAT3 pathway[J].Cell Death and Disease,2019,10(7):1-15.[18]Hang Y,Xiaoyuan W,Xue Z,et al.Integrated analysis of long noncoding RNA associated-competing endogenous RNA as prognostic biomarkers in clear cell renal carcinoma[J].Cancer Science,2018,109(10):3336-3349.[19]Yan DG,Liu N,Chao M,et al.SP1-induced upregulation of long noncoding RNA LINC00313 contributes to papillary thyroid cancer progression via the miR-422a[J].Eur Rev Med Pharmacol Sci,2019,23(3):1134-1144.[20]Yu P,He X,Lu F,et al.Research progress regarding long-chain non-coding RNA in lung cancer: a narrative review[J].J Thorac Dis,2022,14(8):3016-3029.[21]Moya L,Meijer J,Schubert S,et al.Assessment of miR-98-5p,miR-152-3p,miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis[J].International Journal of Molecular Sciences,2019,20(5):1154.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(02):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(02):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(02):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(02):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(02):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[6]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(02):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[7]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(02):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[8]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(02):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[9]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(02):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
[10]杨珑静,马洪波,张献全.抗血管生成药物在非小细胞肺癌中的应用及研究进展[J].医学信息,2019,32(08):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]
　YANG Long-jing,MA Hong-bo,ZHANG Xian-quan.Application and Research Progress of Anti-angiogenic Drugs in Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(02):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]

更新日期/Last Update: 1900-01-01